Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients

Soltész, Beáta; Lukács, János; Szilágyi, Edina; Márton, Erika; Bónizs, Melinda Szilágyi; Penyige, András; Póka, Róbert; Nagy, Bálint

doi:10.1016/j.jbiotec.2019.03.018

Cited by 24 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 CD24 involves in cell proliferation, invasion, metastasis in various cancers and is closely correlated with prognosis of patients. [14][15][16][17] However, the expression level of CD24 in ABC-DLBCL is not clear and whether CD24 is involved in the pathogenesis of ABC-DLBCL also remains unknown.…”

Section: Discussionmentioning

confidence: 99%

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance

Qiao¹,

Li²,

Zhang³

et al. 2021

PGPM

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma and of which the prognosis of activated B-cell-like (ABC) subtype is poor. Although R-CHOP significantly improves the survival of patients with DLBCL, 20% to 40% of patients were resistant to R-CHOP therapy. Thus, screening for candidate therapeutic targets for R-CHOP resistant patients is urgent. The previous researches have shown that CD24 is related to the development, invasion, and metastasis of cancer. Our project aims to clarify the relationship between CD24 and ABC-DLBCL. Patients and Methods: The expression of CD24 mRNA in 118 ABC-DLBCL cases treated with R-CHOP was detected by RNAscope, and the relationship between CD24 expression and R-CHOP treatment response was analyzed. The correlation between CD24 expression and treatment efficiency was further analyzed by data downloaded from the Gene Expression Omnibus (GEO) database. The association between CD24 expression and immune response was conducted using Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) methodology and Gene Ontology (GO) biological process (BP) analysis. Results: The positive expression rate of CD24 mRNA in ABC-DLBCL patients was 38.1% (45/118). Complete Response (CR) rate was significantly higher in patients with CD24 high expression than those with CD24 low expression (P=0.039; 44.4% vs 26.0%). CR rate was significantly different between CD24 high and low expression groups in the analysis of GEO datasets (P=0.003; 83.2% vs 58.0%). The CD24 high expression patients had significantly lower proportions of T cells and nonspecific immune cells in the CIBERSORT analysis. In addition, T−helper 2 cell differentiation and monocyte chemotaxis were repressed in CD24 high expression group in the GO BP analysis. Conclusion: CD24 was correlated with better R-CHOP treatment response and tumor immunosuppression in ABC-DLBCL. CD24 may be a promising signal in treatment and prognosis evaluation in ABC-DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance

Qiao¹,

Li²,

Zhang³

et al. 2021

PGPM

View full text Add to dashboard Cite

show abstract

“…Overexpression of several proteins has been identified in OC-derived exosomes compared to exosomes derived from healthy ovarian epithelial cells and may be useful in the diagnosis or prognosis of OC, for review [52,105]. Among these proteins, epithelial cell surface antigen (EpCAM), CD24, and CA125 have been confirmed by several different studies [106][107][108].…”

Section: Evs As Marker Of Ocmentioning

confidence: 97%

The Role and Clinical Interest of Extracellular Vesicles in Pregnancy and Ovarian Cancer

et al. 2021

View full text Add to dashboard Cite

Ovarian cancer and pregnancy are two states in which the host immune system is exposed to novel antigens. Indeed, both the tumor and placenta must invade tissues, remodel vasculature to establish a robust blood supply, and evade detection by the immune system. Interestingly, tumor and placenta tissue use similar mechanisms to induce these necessary changes. One mediator is emerging as a key player in invasion, vascular remodeling, and immune evasion: extracellular vesicles (EVs). Many studies have identified EVs as a key mediator of cell-to-cell communication. Specifically, the cargo carried by EVs, which includes proteins, nucleic acids, and lipids, can interact with cells to induce changes in the target cell ranging from gene expression to migration and metabolism. EVs can promote cell division and tissue invasion, immunosuppression, and angiogenesis which are essential for both cancer and pregnancy. In this review, we examine the role of EVs in ovarian cancer metastasis, chemoresistance, and immune modulation. We then focus on the role of EVs in pregnancy with special attention on the vascular remodeling and regulation of the maternal immune system. Lastly, we discuss the clinical utility of EVs as markers and therapeutics for ovarian cancer and pre-eclampsia.

show abstract

“…CD24, which encodes a glycosylphosphatidylinositol-linked cell surface ligand for P-selectin, is closely associated with serous ovarian cancer [ 49 ]. CD24 has been identified as one of the most important CSC markers in several cancers, including ovarian and colorectal cancers [ 50 , 51 ].…”

Section: Cell Surface Markers Of Ovarian Cscsmentioning

confidence: 99%

Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells

Yang

Kim

et al. 2021

IJMS

View full text Add to dashboard Cite

Ovarian cancer is a fatal gynecological malignancy. Although first-line chemotherapy and surgical operation are effective treatments for ovarian cancer, its clinical management remains a challenge owing to intrinsic or acquired drug resistance and relapse at local or distal lesions. Cancer stem cells (CSCs) are a small subpopulation of cells inside tumor tissues, and they can self-renew and differentiate. CSCs are responsible for the cancer malignancy involved in relapses as well as resistance to chemotherapy and radiation. These malignant properties of CSCs are regulated by cell surface receptors and intracellular pluripotency-associated factors triggered by internal or external stimuli from the tumor microenvironment. The malignancy of CSCs can be attenuated by individual or combined restraining of cell surface receptors and intracellular pluripotency-associated factors. Therefore, targeted therapy against CSCs is a feasible therapeutic tool against ovarian cancer. In this paper, we review the prominent roles of cell surface receptors and intracellular pluripotency-associated factors in mediating the stemness and malignancy of ovarian CSCs.

show abstract

Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients

Cited by 24 publications

References 23 publications

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance

The Role and Clinical Interest of Extracellular Vesicles in Pregnancy and Ovarian Cancer

Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells

Contact Info

Product

Resources

About